english.prescrire.org > Spotlight > 100 most recent

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

  The 2021 "Prescrire Prize" is awarded
  to 4 books about health and healthcare

The recipients of the 2021 "Prix Prescrire" book awards were announced in Paris on 7 October 2021. The prize is awarded to books or other works of particular interest to the general public and/or healthcare professionals.
07 October 2021

Bulevirtide (Hepcludex°) and chronic hepatitis D: no evidence of efficacy based on clinical endpoints

FEATURED REVIEW Bulevirtide (Hepcludex°) is the first antiviral drug authorised in the European Union for adults with chronic hepatitis D. In this situation, does bulevirtide reduce the incidence and severity of hepatic complications? Does it reduce HDV transmission? And what are its adverse effects?
Full review (3 pages) available for download by subscribers.
1 October 2021

In the October issue of Prescrire International - Multidrug-resistant pulmonary tuberculosis and delamanid: no demonstrated clinical benefit

FREE DOWNLOAD It is helpful to have an antibiotic available which is active against multidrug-resistant mycobacteria. However, as of mid-2021, there is no demonstrated clinical benefit from addition of delamanid to an optimised multiple drug treatment regimen.
Full text available for free download.
1 October 2021

Covid-19 vaccines: glaring inequality

 Editorial  It was estimated in late May 2021 that only 0.3% of the vaccines against covid-19 administered worldwide had been given in the poorest 29 countries. Western leaders are being called upon to do the right thing: a historic opportunity that must be seized.
1 October 2021

Oral tramadol: children still being exposed to the risk of overdose

A concentrated solution of oral tramadol carries a risk of significant overdose through its error-prone dropper.
1 October 2021

Titanium dioxide: is it carcinogenic in humans?

Present in food products, drugs, dietary supplements and cosmetics, titanium dioxide is a possible carcinogen, which should be avoided where possible.
1 October 2021

Supplementary protection certificates: highly profitable for drug companies

A European scheme enables pharmaceutical companies to prolong their market monopoly, sometimes unjustifiably, to the detriment of social welfare systems.
1 October 2021

The Sars-CoV-2 Delta variant: how effective are covid-19 vaccines against this strain?

 COVID-19  In the October edition of Prescrire International, a look at the data available as of mid-2021 regarding the efficacy of covid-19 vaccines against the Delta variant.
1 October 2021

Viral vector covid-19 vaccine ChAdOx1-S (Vaxzevria°) and covid-19. Efficacy in the short term, but a risk of rare, sometimes fatal, thrombosis

FEATURED REVIEW Following two mRNA vaccines, a viral vector vaccine, the covid-19 vaccine ChAdOx1-S (Vaxzevria°, AstraZeneca), has been authorised in the European Union. Like the two mRNA vaccines, this vaccine triggers an immune response against the S glycoprotein of Sars-CoV-2.
Full review (3 pages) available for download by subscribers.
1 September 2021

In the September issue of Prescrire International - Psoriasis and ixekizumab: turn first to standard systemic treatments

FREE DOWNLOAD There is no strong evidence that ixekizumab has greater efficacy than methotrexate in patients with psoriasis. In addition, its adverse effects are less well established than those of standard treatments, particularly in the long term.
Full text available for free download.
1 September 2021

1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90